ananda-pharma-s-action-trial-enters-phase-2-after-first-uk-patient-dose
type: WebPage
primary image of page: ImageObject
  caption: Ananda Pharma’s ACTiON Trial Enters Phase 2… | Cannabivo

Ananda Pharma’s ACTiON Trial Enters Phase 2 After First UK Patient Dose
type: NewsArticle
description: Ananda Pharma has dosed the first patient in the UK’s NIHR-backed ACTiON Phase 2 trial testing CBD-based MRX1 for chemotherapy-induced neuropathy.
language: en
main entity of page: https://cannabivo.com/news/science/ananda-pharma-s-action-trial-enters-phase-2-after-first-uk-patient-dose
date published: 2026-07-23T23:51:14+00:00
date modified: 2026-07-23T23:51:14+00:00
article section: Policy & Regulation
author: Rob Harley
publisher: Cannabivo
  type: Organization
word count: 2963
speakable: SpeakableSpecification
  css selector: .research-article__title
  css selector: .research-article__lead

BreadcrumbList
item list element: Home
  type: ListItem
  position: 1
  item: https://cannabivo.com/
item list element: News
  type: ListItem
  position: 2
  item: https://cannabivo.com/news
item list element: Science
  type: ListItem
  position: 3
  item: https://cannabivo.com/news/science
item list element: Ananda Pharma’s ACTiON Trial Enters Phase 2 After First UK Patient Dose
  type: ListItem
  position: 4
  item: https://cannabivo.com/news/science/ananda-pharma-s-action-trial-enters-phase-2-after-first-uk-patient-dose

FAQPage
main entity: What is the ACTiON trial studying?
  type: Question
  accepted answer: Answer
    text: ACTiON is a UK Phase 2 study evaluating Ananda Pharma’s proprietary CBD-based oral solution MRX1 as a treatment for chemotherapy-induced peripheral neuropathy.
main entity: Who is leading the study?
  type: Question
  accepted answer: Answer
    text: The study is led by Professor Marie Fallon at the University of Edinburgh in Scotland.
main entity: What does NIHR backing mean here?
  type: Question
  accepted answer: Answer
    text: The ACTiON study received an Efficacy and Mechanism Evaluation grant from the UK’s NIHR. The grant is non-dilutive and involves independent scientific scrutiny before approval.
main entity: Has MRX1 been shown to work for CIPN?
  type: Question
  accepted answer: Answer
    text: The supplied facts do not report an efficacy result. An earlier Phase 1 pharmacokinetic trial found a clean safety profile across 20 participants, supporting progression to Phase 2.
main entity: What other MRX1 study is underway?
  type: Question
  accepted answer: Answer
    text: ENDOCAN is a parallel Phase 2 study evaluating MRX1 for endometriosis-associated pain.

Cannabivo
type: Organization
legal name: MS WebX L.L.C.
description: Cannabis club directory and information resource for social clubs in Europe.
contact point: ContactPoint
  contact type: Customer Support
address: PostalAddress
  street address: 7901 4th ST N STE 300
  postal code: 33702
  address locality: St. Petersburg
  address country: US
main entity of page: https://cannabivo.com/pl/o-nas